The NUCB2 antibody is designed to target nucleobindin-2 (NUCB2), a multifunctional protein encoded by the *NUCB2* gene. NUCB2 is widely expressed in various tissues, including the hypothalamus, adipose tissue, and gastrointestinal tract, and is best known as the precursor of nesfatin-1. a peptide hormone implicated in appetite regulation, energy homeostasis, and glucose metabolism. Nesfatin-1 derives from post-translational processing of NUCB2 and interacts with central and peripheral pathways to suppress food intake, modulate insulin secretion, and influence stress responses. Dysregulation of NUCB2/nesfatin-1 has been linked to metabolic disorders such as obesity, diabetes, and anorexia nervosa.
Antibodies against NUCB2 are essential tools for investigating its expression, localization, and physiological roles. They are commonly used in techniques like Western blotting, immunohistochemistry, and ELISA to quantify protein levels, assess tissue distribution, or study interactions with other molecules. Both polyclonal and monoclonal NUCB2 antibodies are available, with specificity validated via knockdown controls or knockout models. Challenges in antibody development include ensuring selectivity due to potential cross-reactivity with homologous proteins or splice variants.
Research applications span neuroscience, endocrinology, and metabolic disease studies, aiming to clarify NUCB2’s role in feeding behavior, energy balance, and its potential as a therapeutic target. Reliable NUCB2 antibodies thus underpin advancements in understanding metabolic and neuroendocrine pathways.